T1	Participants 51 66	prostate cancer
T2	Participants 518 618	945 eligible men with locally advanced prostate cancer were enrolled in a phase 3 trial (RTOG 85-31)
T3	Participants 1632 1673	men with locally advanced prostate cancer
